Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC – Research Report) and Edwards Lifesciences (EW – Research Report).
Alcon (ALC)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Alcon today and set a price target of $80.00. The company’s shares closed last Friday at $66.85, close to its 52-week low of $63.92.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $79.68, representing a 18.6% upside. In a report issued on September 13, Berenberg Bank also initiated coverage with a Buy rating on the stock with a CHF86.00 price target.
See today’s best-performing stocks on TipRanks >>
Edwards Lifesciences (EW)
In a report released today, Marie Thibault from BTIG maintained a Hold rating on Edwards Lifesciences. The company’s shares closed last Friday at $93.35.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $115.29 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALC:
- DHI, LEN, NVR: Housing Stocks to Watch as Rising Mortgage Rates Shake Buyers’ Confidence
- Puyi Inc. Announces Change of Chairman of the Board
- Boston Scientific (BSX) Gets a Buy from BTIG
- Needham Sticks to Their Buy Rating for Velo3D (VLD)
- REPEAT — BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28 Million
